溴隐亭治疗多囊卵巢综合征不育的系统评价

目的 采用循证医学的方法评价溴隐亭治疗多囊卵巢综合征（polycystic ovary syndrome，PCOS）不育的有效性及安全性。方法 计算机检索Pubmed、Cochrane Library、Embase、中国知网数据库、重庆维普数据库、中国生物医学文献数据库及万方数据库，寻找国内外随机对照试验，检索时间均为建库至2017年8月，按照纳入与排除标准筛选、纳入文献，然后评价方法学质量，最后采用RevMan 5.0软件进行meta分析。结果 纳入6个随机对照试验，共469例患者，其中溴隐亭治疗组231例，对照组238例。Meta分析结果显示，溴隐亭治疗组与对照组相比较，在排卵率（合并效应量=0.20，P=0.84）、妊娠率（合并效应量=1.88，P=0.06）、卵泡发育（合并效应量=0.51，P=0.61）及流产率（合并效应量=0.98，P=0.33）方面，差异均无统计学意义；而在成熟卵泡数（合并效应量=3.62，P=0.000 3）及子宫内膜厚度（合并效应量=2.77，P=0.006）方面，2组比较差异均有统计学意义，溴隐亭治疗组成熟卵泡数及子宫内膜厚度均高于对照组。结论 溴隐亭虽然可增加PCOS患者成熟卵泡个数及子宫内膜厚度，但不能改善卵泡发育，也不增加排卵率、妊娠率及流产率。鉴于本研究纳入的文献样本量较小，且存在一定的方法学质量问题，导致可能有较高的偏倚风险，因此结论尚待设计严谨的多中心、大样本研究加以论证。

Analysis of Bromocriptine in the Treatment of Polycystic Ovary Syndrome: A Systematic Review

Objective To assess the effectiveness and safety of bromocriptine in women with infertility, caused by polycystic ovary syndrome. Methods Pubmed database, the Cochrane Library, the Embase database, the CNKI database, the VIP database, the CBM database and the Wanfang database were searched to identify relevant randomized controlled trials(RCTs) from the day of database builded to August 2017. RCTs which met the inclusion criteria were selected, reviewed and analysised by Revman 5.0 software. Results Six RCTs involving 469 patients were included in this study, 231 patients in the bromocriptine group and 238 patients in the control group. Meta-analysis results showed that the rates of ovulation(Z=0.20, P=0.84), pregnancy(Z=1.88, P=0.06), follicular development(Z=0.51, P=0.61) and abortion(Z=0.98, P=0.33) did not differ significantly among the groups. However, the mature follicle(Z=3.62, P=0.000 3) and the endometrial thickness(Z=2.77, P=0.006) were significantly greater in the bromocriptine group than those in control group. Conclusion It is found that no evidence suggesting that bromocriptine improves the rates of ovulation, pregnancy, follicular development and abortion, though it showed benefit in terms of mature follicle and endometrial thickness. Limitations included imprecision(small design trials) and poor reporting of study methods. Large, well-designed RCTs are necessary to further evaluate the role of bromocriptine in polycystic ovary syndrome.